Immuvera Therapeutics As

05/10/2025

🎙️ Daglig leder i Immuvera Therapeutics, Jørund Sollid, har gjestet Radforsk sin podcast "Radium"!

I episoden deler han historien og veien videre for Immuvera Therapeutics, litt innsikt fra sin egen profesjonelle reise og hvordan vi kan bygge en sterkere helsenæring i Norge.

👉 Lytt til episoden på Soundcloud https://tinyurl.com/Immuverasoundcloud eller på Spotify https://tinyurl.com/Immuveraspotify

Immuvera utvikler en ny behandling mot kreft hos hunder – med mål om å forebygge og behandle lungemetastaser. I 2026 starter vi vår større randomiserte klinisk studie på 40 hunder som skal gjennomføres ved 20 klinikker i Europa. Går alt etter planen starter vi dealxiten i slutten av 2027 og vår immunterapi får sin regulatoriske godkjenning og markedsintroduksjon allerede i 2029 til glede for alle hundeiere.

I den forbindelse vil vi også nå hente midler via Folkeinvest!

👉 følg vår case på https://folkeinvest.no/kampanjer?kommer-snart=immuvera-therapeutics

hashtag hashtag hashtag hashtag

RADIUM · Episode

05/10/2025

🎉 Stor nyhet! 🎉

Immuevra Therapeutics har fått Limited Market Authorisation for vår immunterapi rettet mot behandling av kreft hos hunder!

Godkjenningen åpner for raskere bruk samtidig som vi fortsetter å samle inn robuste data om effekt og sikkerhet. 💪

Hva betyr det i praksis?

Tidligere tilgang til en lovende behandling for pasienter med stort behov

Tett oppfølging og innsamling av real-world evidence

Et tydelig veiskille på veien mot full markedsføringstillatelse

Vi er utrolig takknemlige for innsatsen fra pasienter, pårørende, klinikere og våre samarbeidspartnere som har gjort dette mulig.

👉 Følg siden vår for oppdateringer og neste milepæler.

16/09/2025

We’re thrilled to share that our first key patent family protecting our lead product Nebumet did officially receive the first grant in a major market during the summer holidays 🎉

We will now continue to register the patent in other territories, add it to our renewal schedule and mark relevant products accordingly.

Jørund Sollid, CEO Immuvera Therapeutics: "Securing this grant strengthens naturally our IP portfolio, and shows to our partners and investors that our science is novel and are being protected, supporting our value generation model."

We’re excited to keep building value and bringing innovative cancer therapies to our four‑legged patients—and eventually to humans.

16/09/2025

We are changing our name! 🎉

After reflecting on our mission and growth, Alv B AS is now Immuvera Therapeutics.

Why the change? We wanted a name that clearly signals what we do and what drives us. Immuvera combines “immuno”, the immune‑based therapies we build, with “veritas,” Latin for truth. Our focus remains on developing innovative cancer treatments for dogs, drawing insights from naturally occurring cancers that can inform human medicine. The name Immuvera better reflects this unique combination of immunotherapy innovation and comparative oncology, and it clarifies our purpose for partners, investors and pet owners.

While the name is new, our mission and team are not. We’re continuing to advance therapies heading toward clinical trials and partnering with veterinarians, researchers and investors who share our vision.
Thank you for supporting us as we evolve. Join us on this journey to bring cutting‑edge immunotherapies to our four‑legged companions and beyond.

16/09/2025

We’re thrilled to welcome two outstanding additions to the Alv B team!

Gry Stensrud joins us as Chief Technical Officer. With a Ph.D. in Pharmaceutical Technology and 25+ years in biotech, pharma, and med tech, Gry brings deep expertise from companies like GE Healthcare, Photocure, and Lytix Biopharma — spanning CMC, quality, and pharmaceutical development from preclinical to commercial scale.

Anja Holm comes onboard as Head of Regulatory Affairs. A trained veterinarian from the University of Copenhagen, Anja has nearly 25 years’ experience in veterinary regulatory affairs, including 12 years in the CVMP at the European Medicines Agency, where she also served as Chair.

With Gry and Anja, we’re strengthening our cross-disciplinary expertise and our position in health tech and biotech.

Welcome to Alv B, Gry Stensrud and Anja E. H. Holm! We are excited to have you with us! 🚀

01/08/2025

We’re thrilled to welcome two outstanding additions to the Alv B team!

Gry Stensrud joins us as Chief Technical Officer. With a Ph.D. in Pharmaceutical Technology and 25+ years in biotech, pharma, and med tech, Gry brings deep expertise from companies like GE Healthcare, Photocure, and Lytix Biopharma — spanning CMC, quality, and pharmaceutical development from preclinical to commercial scale.

Anja Holm comes onboard as Head of Regulatory Affairs. A trained veterinarian from the University of Copenhagen, Anja has nearly 25 years’ experience in veterinary regulatory affairs, including 12 years in the CVMP at the European Medicines Agency, where she also served as Chair.

With Gry and Anja, we’re strengthening our cross-disciplinary expertise and our position in health tech and biotech.

Welcome to Alv B, Gry Stensrud and Anja E. H. Holm! We are excited to have you with us! 🚀